US EditionPublished • loading... • Updated
GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine
- GC Biopharma has signed an agreement with Curevo Vaccine for contract manufacturing rights for amezosvatein, a shingles vaccine under development.
- Under this agreement, GC Biopharma will produce part of the commercial supply of amezosvatein for global markets.
- Curevo Vaccine is conducting a Phase 2 study involving 640 adults aged 50 and older, with plans to complete it by 2026.
- This agreement is seen as a key step in securing long-term growth for GC Biopharma's global vaccine business.
Insights by Ground AI
30 Articles
30 Articles
The Times of Northwest Indiana+29 Reposted by 29 other sources
GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine
YONGIN, South Korea, Oct. 13, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant…
·Cherokee County, United States
Read Full ArticleCoverage Details
Total News Sources30
Leaning Left7Leaning Right6Center9Last UpdatedBias Distribution41% Center
Bias Distribution
- 41% of the sources are Center
41% Center
L 32%
C 41%
R 27%
Factuality
To view factuality data please Upgrade to Premium
